施工実績

Bieche I, Parfait B, Tozlu S, Lidereau Roentgen, Vidaud Yards: Quantitation out-of androgen receptor gene phrase for the sporadic breast tumors by real-go out RT-PCR: facts one to MYC are https://datingranking.net/tr/naughtydate-inceleme/ an AR-regulated gene. Carcinogenesis. 2001, twenty-two (9): 1521-1526. /carcin/twenty-two.9.1521.

Bratthauer GL, Lininger RA, Son YG, Tavassoli FA: Androgen and you can the hormone estrogen receptor mRNA reputation within the apocrine carcinomas. Diagn Mol Pathol. 2002, eleven (2): 113-118. 9606-200206000-00008.

Gatalica Z: Immunohistochemical analysis off apocrine breast sores. Consistent over-phrase out of androgen receptor accompanied by losing the hormone estrogen and progesterone receptors for the apocrine metaplasia and you may apocrine carcinoma into the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.

Are J Clin Pathol

Soreide JA, Lea OA, Varhaug JE, Skarstein A great, Kvinnsland S: Androgen receptors during the operable breast cancer: regards to almost every other steroid hormones receptors, correlations so you can prognostic items and you can predictive well worth having effect of additive tamoxifen cures. Eur J Surg Oncol. 1992, 18 (2): 112-118.

Bayer-Garner IB, Smoller B: Androgen receptors: an excellent marker to improve awareness to possess distinguishing cancer of the breast during the surface metastasis of unknown pri, thirteen (2): 119-122. /modpathol.3880021.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic pastime and you will scientific implications. J Clin Oncol. 2000, 18 (5): 1135-1149.

Pang ST, Flores-Morales A beneficial, Skoog L, Chuan YC, Nordstedt Grams, Pousette An excellent: Control regarding matrix metalloproteinase 13 expression by the androgen during the prostate malignant tumors. Oncol Agent. 2004, 11 (6): 1187-1192.

Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.

Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Research of the prognostic need for androgen receptor phrase during the metastatic breast cancer. Virchows Arch. 2006, 449 (1): 24-29. /s00428-006-0213-6.

Parker RL, Hunter DG, Lesack DW, Cupples JB, Offer DR, Akbari Yards, Gilks CB: Analysis regarding interlaboratory variation on the immunohistochemical determination out-of estrogen receptor updates using a cancer of the breast tissues microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.

Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Study of matrix metalloproteinases and their inhibitors when you look at the breast cancer. Br J Cancers. 2007, 96 (6): 903-911. /sj.bjc.6603666.

Narita D, Raica Meters, Suciu C, Cimpean An effective, Anghel A good: Immunohistochemical phrase from androgen receptor and you can prostate-specific antigen during the breast cancer. Folia Histochem Cytobiol. 2006, forty-two (3): 165-172.

Egeblad Meters, Werb Z: The qualities on matrix metalloproteinases into the cancer development. Nat Rev Cancer. 2002, dos (3): 161-174. /nrc745.

Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–with the head phase regarding malignant tumors?. Malignant tumors Telephone. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.

Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Elizabeth, Martinez Ac: The fresh new matrix metalloproteinase-9 controls the newest insulin-such increases foundation-caused autocrine effect for the DU-145 carcinoma structure. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..

Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel Age, Matrisian LM, Mareel Meters: Launch of an intrusion promoter E-cadherin fragment by the matrilysin and stromelysin-step 1. J Mobile Sci. 2001, 114 (Pt step 1): 111-118.

Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] phrase selects to possess tissues with just minimal susceptibility to help you apoptosis. Neoplasia. 2001, step three (6): 459-468. /sj.neo.7900190.

CO;2-H

Stetler-Stevenson WG: Matrix metalloproteinases from inside the angiogenesis: a moving address to have therapeutic intervention. J Clin Invest. 1999, 103 (9): 1237-1241. /JCI6870.

Cornelius Los angeles, Nehring LC, Harding Elizabeth, Bolanowski Yards, Welgus HG, Kobayashi DK, Enter RA, Shapiro SD: Matrix metalloproteinases build angiostatin: outcomes into the neovascularization. J Immunol. 1998, 161 (12): 6845-6852.

Jiang Y, Goldberg ID, Shi YE: State-of-the-art roles of tissues inhibitors out-of metalloproteinases in the cancers. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.